Alligator Bioscience publishes Annual Report for 2022
Lund, Sweden, March 24, 2023 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2022 has been publi ...
Notice of extraordinary general meeting in Alligator Bioscience AB
The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the extraordinary general meeting to be held on Monday 24 ...
Alligator intends to carry out a 91 percent secured rights issue of units of approximately SEK 199 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience Announces KOL Interview on Mitazalimab and the Positive Interim Results from the OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer
Interview features OPTIMIZE-1 Principal Investigator Jean-Luc Van Laethem from Erasmus Hospital and Alligator CMO Sumeet Ambarkhane OPTIMIZE ...
Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB
Alligator Bioscience AB (publ) today announces that Tova Landström, PhD, Medical Science Director at Alligator, has been appointed as employ ...
Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB
Laura von Schantz, employee representative, has resigned from the Alligator Bioscience AB Board of Directors, effective February 14, 2023, f ...
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
Trial to Evaluate Safety, Tolerability and Clinical Activity in Solid Tumors Expressing 5T4 Lund, Sweden, and Seattle, Washington, February ...
Alligator Bioscience Announces the Promotion of Laura von Schantz to Chief Technology Officer
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the promotion of Laura von Schantz to Chief Technology O ...
Alligator Bioscience AB reports full year financial results for 2022 and for Q4 2022 and provides a business update
Interim results from mitazalimab OPTIMIZE-1 Phase 2 trial in pancreatic cancer exceed 50% Objective Response Rate, the trial passes pre-plan ...